Volume 21, Issue 1

Behind the scenes, the Governing Board has been fine-tuning the Scientific Programme for the ECCO Congress, to optimise the use of time and space and to give extra focus to popular formats. So, before you finalise your travel arrangements for ECCO’27 in Copenhagen, please note the following key changes.

The 21st Congress of ECCO, Stockholm, Sweden – Inflammatory Bowel Diseases 2026, held on February 18-21, 2026, attracted a total number of 7,388 delegates from 99 different countries. Since the inaugural ECCO Congress in 2006 in Amsterdam, at which there were 350 delegates, participant numbers have steadily increased. We are pleased that such a high number of delegates were able to take part in the ECCO’26 Congress in Stockholm.

The 21st Congress of ECCO once again showcased the breadth and depth of innovation in Inflammatory Bowel Disease (IBD), spanning fundamental science, translational research, clinical trials and real-world evidence. The 16 selected Digital Oral Presentations (DOPs) highlighted key advances in precision medicine, novel therapeutics and disease monitoring, reflecting the rapidly evolving landscape of IBD care.

Dear ECCO Family, In association with the newly launched ECCO LinkedIn Account, a major effort was undertaken at ECCO’26 to upgrade the picture gallery of our annual congress: https://ecco-ibd.eu/ecco26/our-congress/gallery.

Inflammatory Bowel Disease (IBD) is now evolving as a global condition with rising incidence across all regions of the world. We are attempting to gain a deeper understanding of this new global evolution of IBD, but in addition coordinated global efforts are needed to address disparities in care, access and implementation of best practices.As a well-established organisation with global membership, strong scientific leadership, educational programmes and widely recognised guidelines, ECCO is fully committed to contributing to this global initiative.